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ABSTRACT
Components of the mitochondrial electron transport chain have recently gained 
much interest as potential therapeutic targets. Since mitochondria are essential for 
the supply of energy that is required for both angiogenic and tumourigenic activity, 
targeting the mitochondria represents a promising potential therapeutic approach 
for treating cancer. Here we investigate the established anti-angiogenesis drugs 
combretastatin A4, thalidomide, OGT 2115 and tranilast that we hypothesise are 
able to exert a direct anti-cancer effect in the absence of vasculature by targeting the 
mitochondria. Drug cytotoxicity was measured using the MTT assay. Mitochondrial 
function was measured in intact isolated mitochondria using polarography, fluorimetry 
and enzymatic assays to measure mitochondrial oxygen consumption, membrane 
potential and complex I–IV activities respectively. Combretastatin A4, OGT 2115 
and tranilast were both shown to decrease mitochondrial oxygen consumption. OGT 
2115 and tranilast decreased mitochondrial membrane potential and reduced complex 
I activity while combretastatin A4 and thalidomide did not. OGT 2115 inhibited 
mitochondrial complex II–III activity while combretastatin A4, thalidomide and 
tranilast did not. Combretastatin A4, thalidomide and OGT 2115 induced bi-phasic 
concentration-dependent increases and decreases in mitochondrial complex IV activity 
while tranilast had no evident effect. These data demonstrate that combretastatin 
A4, thalidomide, OGT 2115 and tranilast are all mitochondrial modulators. OGT 2115 
and tranilast are both mitochondrial inhibitors capable of eliciting concentration-
dependent reductions in cell viability by decreasing mitochondrial membrane potential 
and oxygen consumption.
INTRODUCTION
Angiogenic neovascularisation is central to the 
pathogenesis and haematogenous dissemination of 
malignant tumours [1]. The angiogenic sprouting and 
intussusceptive growth of newly formed blood vessels 
is critically dependent on the provision of metabolic 
energy, in the form of adenosine 5ʹ-triphosphate (ATP), 
by mitochondrial oxidative phosphorylation (OXPHOS) 
[2]. A plethora of recent evidence has also demonstrated 
that the cancer cells within tumours are significantly more 
reliant on mitochondrial oxidative metabolism to meet 
their metabolic energy demands than has been generally 
assumed since the introduction of the Warburg hypothesis 
almost 60 years ago [2–5]. These observations, when 
taken together, indicate a pivotal role for mitochondria 
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in the pathogenesis of cancer, making them a promising 
molecular target for anti-cancer therapies.
It has been demonstrated that mitochondria are 
unexpected targets for a range of drugs. The widely 
prescribed anti-diabetic agent metformin has been 
associated with a reduced incidence of cancer amongst 
type-II diabetic patients treated with metformin [6]. Data 
suggests that metformin possesses direct anti-cancer 
activity mediated by effective inhibition of mitochondrial 
complex I [7]. In addition, a number of other agents have 
been identified that act at the mitochondria to cause cancer 
cell death in vitro, including tricyclic antidepressants such 
as chlorimipramine [8]; vanilloids such as capsaicin [9]; 
and cannabinoids such as Δ9-tetrahydrocannabinol (THC), 
the psychoactive compound in Cannabis sativa [10].
Several small molecule inhibitors of angiogenesis 
have been shown to possess both anti-angiogenic 
and direct anti-cancer properties in vitro and in vivo 
[11–16]. Due to the heavy reliance of both angiogenesis 
and tumorigenesis on mitochondrial function, the ability 
of these agents to independently target both the tumour 
vasculature and the malignant cell mass implies that each 
might have at least one mitochondrial target of action.
In this study we measured the in vitro cytotoxicity of 
the anti-angiogenic drugs combretastatin A4, thalidomide, 
OGT 2115 and tranilast on MCF-7 human breast cancer 
and NCI-H460 human non-small cell lung cancer cell lines 
using the MTT assay. We also investigated the potential 
underlying cell death modalities by assessing cellular 
morphology under fluorescence microscopy following 
staining of cytoskeletal F-actin and nuclei, as well as 
fluorimetric measurement of cellular caspase-3 activity. 
In addition, we also measured oxygen consumption and 
membrane potential in intact isolated mitochondria, and 
the specific enzyme activities of mitochondrial complex 
I [EC 1.6.5.3], mitochondrial complex II–III [EC 1.8.3.1] 
and mitochondrial complex IV [EC 1.9.3.1] in the 
presence of a range of concentrations of each drug.
RESULTS
Anti-angiogenic drugs inhibited the proliferation 
of MCF-7 and NCI-H460 cells
MCF-7 human breast cancer and NCI-H460 human 
non-small cell lung carcinoma cells were treated with a 
range of concentrations (1 nM - 100 μM) of each anti-
angiogenic drug for 72 hours, after which cell viability 
was measured by an MTT assay. Figure 1 shows that 
the viability of both MCF-7 and NCI-H460 cells was 
reduced at all concentrations of combretastatin A4 used 
relative to the solvent control (1% DMSO). There was 
a concentration-dependent decrease in MCF-7 and 
NCI-H460 cell viability at OGT 2115 concentrations of 
0.1 μM and above. When MCF-7 cells were incubated 
with thalidomide there was a significant concentration-
dependent decrease in cell viability at drug concentrations 
above 1 μM, while NCI-H460 cell viability was only 
reduced at a thalidomide concentration of 100 μM. 
Tranilast only caused a significant decrease in viable 
MCF-7 cell number at a concentration of 100 μM, while 
no reduction in viable NCI-H460 cell mass was evident at 
any of the concentrations of tranilast used.
Fluorescence microscopy showed changes in 
cytoskeletal and nuclear morphology
MCF-7 and NCI-H460 cell morphology was 
examined under fluorescence microscopy following 
24 hours exposure to a single concentration (100 μM) of 
each drug at which a significant reduction in viable cell 
number was evident in MTT assays (Figure 2 and Figure 3, 
respectively). MCF-7 cells exposed to combretastatin A4 
were smaller in size, more rounded in shape and notably 
less well attached to the growth surface when compared 
to control cells exposed to 1% DMSO; the number of 
cytoskeletal attachments were also less numerous and 
the cell margins appeared irregularly shaped. Cell nuclei 
showed evidence of pyknotic DNA condensation and were 
generally smaller in size when compared to nuclei of cells 
in the control group. In thalidomide treated MCF-7 cells 
both the cytoskeletal and nuclear morphology were largely 
normal. In OGT 2115 treated MCF-7 cells the cytoskeletal 
staining showed evidence of swelling and rupture of cells; 
the integrity of cytoskeletal structure was completely 
compromised and F-actin appeared fragmented and 
widely dispersed. Similarly, nuclei displayed characteristic 
features of dissolution (karyolysis); nuclei were much 
larger in area and flattened in appearance when compared 
to control cell nuclei, and there were numerous large 
vacuole-like regions present that were devoid of the DAPI 
stain. In cells exposed to tranilast there was no obvious 
evidence of changes to either cytoskeletal or nuclear 
morphology and they had an overall appearance similar to 
that of those in control samples.
In NCI-H460 cells exposed to either combretastatin 
A4 or OGT 2115 the pattern of cytoskeletal staining was 
strongly suggestive of necrotic cell death showing signs 
of cell swelling and rupture; the integrity of cytoskeletal 
structure was completely compromised and F-actin 
appeared fragmented and widely dispersed compared to 
that of control cells treated with 1% DMSO. Similarly, 
nuclei displayed characteristic features of karyolysis 
and numerous large vacuole-like regions present that 
were devoid of DAPI stain. In thalidomide treated cells 
the cytoskeletal morphology was suggestive of the early 
stages of apoptosis; the cells were generally smaller and 
more rounded than control samples and there was some 
evidence of cytoplasmic blebbing or zeiosis. In addition, 
both the size of the cell margin and the number of 
cytoskeletal attachments to the growth surface were visibly 
reduced. There was no evidence of obvious changes in 
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nuclear morphology. Cells exposed to tranilast showed 
no obvious evidence of changes to either cytoskeletal or 
nuclear morphology and had an overall appearance that 
was similar to that of control cells.
Combretastatin A4 and thalidomide induced 
caspase-3 activity
Caspase-3 activity was measured fluorimetrically 
over a 24-hour period following treatment of either MCF-7 
or NCI-H460 cells with a 100 μM concentration of each 
anti-angiogenic drug, 1 μM staurosporine (positive control) 
or 1% DMSO (negative control) (Figure 4). Incubation 
of MCF-7 cells in the presence of 1 μM staurosporine, 
a positive control for inducing apoptosis [17], elicited 
significant caspase-3 activity after 2 hours, which rose to 
a peak at 8 hours and then gradually declined thereafter; 
while in the NCI-H460 cell line a marked increase in 
caspase-3 activity was measured after 8 hours of exposure 
which remained significantly elevated from 16 hours 
Figure 1: MTT cell viability assays. MTT assays demonstrating the relative viability of MCF-7 human breast cancer cells (A) and 
NCI-H460 human non-small cell lung cancer cells (B) following a 72-hour period of exposure to a range of concentrations (1 nM–100 μM) 
of either combretastatin A4 (IC50 < 1 nM for MCF-7 and NCI-H460), OGT 2115 (IC50 = 0.26 μM for MCF-7 and IC50 = 0.24 μM for 
NCI-H460), thalidomide (IC50 = 3.03 μM for MCF-7 and IC50 > 100 μM for NCI-H460) or tranilast (IC50  > 100 μM for MCF-7 and 
NCI-H460). Data are expressed as means ± SEM for three independent experiments (n = 3). The difference between control and treatment 
groups at each drug concentration was determined by two-way ANOVA followed by Dunnett’s multiple comparison test. The asterisk 
symbol (*) is used to denote statistical significance in the difference between experimental and negative control values (P ≤ 0.05).
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Figure 2: MCF-7 cell morphology following 24-hours exposure to anti-angiogenic drugs. Fluorescence photomicrographs 
illustrating NCI-H460 cell cytoskeletal and nuclear morphology following a period of 24 hours exposure to 100 μM combretastatin A4 (A) 
100 μM thalidomide (B) 100 μM OGT 2115 (C) 100 μM tranilast (D) and control cells exposed to 1% DMSO (E). Cytoskeletal F-actin 
fibres are stained with AlexaFluor488-phalloidin (green) and superimposed on the nuclear dsDNA stained with DAPI (blue). v = vacuole-
like structures, ca = cytoskeletal attachments.
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Figure 3: NCI-H460 cell morphology following 24-hours exposure to anti-angiogenic drugs. Fluorescence photomicrographs 
illustrating cytoskeletal and nuclear morphology of MCF-7 cells following a period of 24 hours exposure to 100 μM combretastatin A4 
(A) 100 μM thalidomide (B) 100 μM OGT 2115 (C) 100 μM tranilast (D) or and control cells exposed to 1% DMSO (E). Cytoskeletal
F-actin fibres are stained with AlexaFluor488-phalloidin (green) and superimposed on the nuclear dsDNA stained with DAPI (blue).
v = vacuole-like structures.
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to 24 hours post-treatment. Treatment of MCF-7 cells 
with combretastatin A4 induced a significant increase in 
caspase-3 activity after 16 hours of incubation, which 
was elevated further at 24 hours. Incubation of cells with 
thalidomide induced a significant time-dependent increase 
in caspase-3 activity between 8 and 24 hours. The caspase-3 
activity value for cells incubated with thalidomide at 24 
hours was greater than that measured for staurosporine at 
the same time point. Treatment with OGT 2115, tranilast 
or 1% DMSO did not result in any significant increase in 
caspase-3 activity throughout the 24-hour time-course. 
NCI-H460 cells treated with combretastatin A4, OGT 2115 
or tranilast did not demonstrate any significant increase in 
caspase-3 activity throughout the 24-hour time-course. 
NCI-H460 cells incubated with thalidomide showed a 
significant increase in caspase-3 activity above basal levels 
only after 24 hours.
Combretastatin A4, OGT 2115 and tranilast 
altered integrated mitochondrial function
Combretastatin A4, OGT 2115 and tranilast all 
induced a significant concentration-dependent decrease 
in mitochondrial oxygen consumption relative to the 
small change induced by DMSO alone (Figure 5). 
Thalidomide did not significantly alter the mitochondrial 
oxygen consumption rate. In addition, no significant 
change in either complex I-linked or complex II-linked 
mitochondrial membrane potential (Figure 6) was 
observed following three sequential 10 μM additions 
of either combretastatin A4 or thalidomide compared to 
control measurements made in the presence of equivalent 
volumes of DMSO. In both cases, addition of the 
mitochondrial-uncoupling agent FCCP depolarised the 
mitochondria, completely dissipating the mitochondrial 
membrane potential and resulting in a large increase in 
fluorescence that indicated that no membrane potential had 
been lost following drug exposure. Sequential addition of 
tranilast at 10 μM incremental concentrations resulted in 
corresponding small increases in fluorescence intensity, 
indicating a small concentration-dependent decrease in 
mitochondrial membrane potential. Addition of OGT 
2115 (f.c. 10 μM) initially resulted in a decrease in 
fluorescence, indicating mitochondrial hyperpolarisation, 
i.e. an increase in the mitochondrial membrane potential,
after which membrane potential appeared to return to the
basal level. On further addition of OGT 2115 (f.c. 20 μM)
a large and rapid increase in fluorescence was elicited,
Figure 4: Caspase-3 activity assays. Caspase-3 activity in MCF-7 (A and B) and NCI-H460 cells (C and D) treated with either 
100 μM combretastatin  A4, 100 μM thalidomide, 100 μM OGT 2115, 100 μM tranilast or 1 μM staurosporine (as a positive control) at 
intervals of 0, 1, 2, 4, 8, 16 or 24 hours following treatment. Data are expressed as means ± SEM for three independent experiments (n = 3). 
The differences between control and treatment groups at each time point were determined by two-way ANOVA followed by Dunnett’s 
multiple comparison test. The asterisk symbol (*) is used to denote statistical significance in the difference between experimental 
and negative control values  (P ≤ 0.05).
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corresponding to a rapid loss of mitochondrial membrane 
potential. The final addition of OGT 2115 (f.c. 30 μM) 
produced minor hyperpolarisation followed by the loss 
of virtually all remaining membrane potential. Addition 
of the mitochondrial uncoupling agent FCCP resulted in 
very little further increase in fluorescence, indicating that 
virtually all of the membrane potential had previously 
been dissipated by OGT 2115. The same pattern of 
hyperpolarisation and subsequent complete depolarisation 
was achieved when a single addition of OGT 2115 was 
made to achieve a final concentration of 10 μM.
All anti-angiogenic compounds tested inhibited 
mitochondrial complex I activity
Mitochondrial complex I activity was measured in the 
presence of a range of concentrations (0.01 μM–100 μM) 
of combretastatin A4, OGT 2115, thalidomide or tranilast 
relative to activity measurements recorded for control samples 
exposed to 1% DMSO (Figure 7). Mitochondrial complex 
I activity was not significantly changed at concentrations 
of combretastatin A4 below 0.8 μM, but was significantly 
reduced, in a tri-phasic manner, at concentrations of 
1.6 μM – 100 μM. Significant decreases in mitochondrial 
complex I activity were measured at all concentrations of 
OGT 2115 used and the inhibition of mitochondrial complex 
I activity was increased in a concentration-dependent 
manner at OGT 2115 concentrations above 0.4 μM. 
Mitochondrial complex I activity was significantly reduced 
at all concentrations of thalidomide and tranilast used.
OGT 2115 inhibited mitochondrial complex  
II–III activity
Figure 8 shows mitochondrial complex II–III activity 
in the presence of a range of concentrations (0 μM –100 μM) 
of combretastatin A4, thalidomide, OGT 2115 or tranilast. 
Combretastatin A4, thalidomide and tranilast did not 
cause significant alterations in mitochondrial complex 
II–III activity at any of the concentrations of drugs used. 
Mitochondrial complex II–III activity was not significantly 
changed at concentrations of OGT 2115 below 25 μM 
but was significantly decreased at concentrations of 
25 μM–100 μM.
Combretastatin A4, thalidomide and OGT 2115 
altered mitochondrial complex IV activity
Figure 9 shows mitochondrial complex IV 
activity in the presence of a range of concentrations 
(0 μM – 100 μM) of combretastatin A4, thalidomide, 
OGT 2115 or tranilast. Mitochondrial complex IV 
activity was significantly increased at combretastatin A4 
concentrations of 0.01 μM – 0.4 μM but was significantly 
decreased at concentrations above 12.5 μ M. Similarly, 
thalidomide concentrations of 0.01 μM – 0.8 μM caused a 
significant increase in mitochondrial complex IV activity, 
while concentrations in excess of 50 μM resulted in 
significantly decreased activity. OGT 2115 caused dose-
dependent decreases in mitochondrial complex IV activity 
at concentrations above 12.5 μM. Tranilast did not cause 
any alteration to mitochondrial complex IV activity 
relative to control measurements.
DISCUSSION
Combretastatin A4
Combretastatin A4 has been reported to elicit 
significant cytotoxic effects in numerous cancer cell 
lines, including both MCF-7 and NCI-H460 lineages 
[18–20]. Mendez-Callejas et al. [21] demonstrated that 
combretastatin A4 leads “to (mitochondrial) cytochrome 
c release, alteration in the mitochondrial membrane 
Figure 5: Mitochondrial oxygen consumption measurements. Mitochondrial oxygen consumption in state-3 respiration (+ ADP) 
following sequential addition of either combretastatin A4 (A), thalidomide (A) OGT 2115 (B) or tranilast (B) to final concentrations of 
10 μM, 20 μM and 30 μM. Control samples were exposed to equivalent volumes of DMSO. Data are expressed as means ± SEM for 
three biologically independent repeat experiments (n = 3). The difference between control and treatment groups at each time point was 
determined by two-way ANOVA followed by Dunnett’s multiple comparison test. The asterisk symbol (*) is used to denote statistical 
significance in the difference between experimental and negative control values (P ≤ 0.05).
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polarisation, cell cycle arrest at the G2/M-phase, and 
cell death”. Previous studies are consistent with the 
data shown here, in which both MCF-7 and NCI-H460 
cell viability was markedly reduced at concentrations of 
combretastatin A4 exceeding 1nM. MCF-7 cells treated 
with combretastatin A4 demonstrated morphological 
changes which included cell shrinkage, loss of attachment 
to the growth surface and early stages of nuclear 
condensation; changes which are typically characteristic 
of apoptosis [22]. In addition, combretastatin A4 induced 
significantly increased caspase-3 activity between 8 and 
16 hours following exposure to combretastatin A4. When 
taken together, these data suggest that combretastatin 
A4 reduced MCF-7 cell viability by induction of 
Figure 6: Mitochondrial membrane potential measurements. NADH- (A–C) and FADH2-linked (D–F) mitochondrial membrane 
potential measurements made using rhodamine-123 (Rh-123) in isolated rat heart mitochondria. On addition of mitochondria to the 
fluorimeter cuvette, the fluorescence intensity decreased as rhodamine-123 partitioned into the matrices of energised mitochondria. Three 
sequential additions of each drug or DMSO (vehicle control) were made in each experiment to achieve final concentrations of 10 μM, 
20 μM and 30 μM of combretastatin A4, thalidomide, OGT 2115 and tranilast or equivalent concentrations of DMSO (final concentrations 
of 0.1%, 0.2% and 0.3% (v/v) in solution, respectively). Subsequently, the mitochondrial uncoupling agent FCCP was used to completely 
depolarise the mitochondria and dissipate any remaining membrane potential. The fluorimetric traces displayed are representative of n = 3 
independent experiments.
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apoptosis. NCI-H460 cells treated with combretastatin 
A4 demonstrated cytoplasmic swelling, loss of normal 
cytoskeletal structure, evidence of cell membrane rupture, 
and karyolytic nuclear dissolution; changes which are 
typically characteristic of necrosis [23]. In addition, 
combretastatin A4 did not induce any caspase-3 activity 
in NCI-H460 cells over 24 hours of exposure. When 
taken together, these data indicate that combretastatin A4 
reduced adherent NCI-H460 cell viability by induction of 
necrotic cell death.
Combretastatin A4 had the same effect on cell death 
at 1 nM and at 100 μM in both the NCI-460 and MCF-
7 cells lines. However, it has been shown that there is a 
small population in both NCI-460 cells [24] and MCF-7 
cells [25] that have features of cancer stem cells, such as 
increased resistance to drugs. Therefore, these data could 
indicate that the cells left following treatment with the 
various drugs are in fact a cancer stem cell sub-population.
While significant decreases in mitochondrial 
complex I activity were measured in the presence of 
combretastatin A4, even at relatively low concentrations, 
there was no evident change in mitochondrial membrane 
potential under either mitochondrial complex I-linked 
(NADH-linked) or complex II-linked (FADH2-linked) 
respiration at combretastatin concentrations of 10 μM 
to 30 μM. These observations might be at least partially 
explained by the mitochondrial threshold hypothesis, as 
described by Calabrese et al. [26], which proposes that 
the activity of a particular respiratory chain complex 
must be decreased to a critical “threshold” level before a 
significant decrease in integrated mitochondrial function 
(mitochondrial oxygen consumption, transmembrane 
potential or ATP synthesis) is able to occur. An 
additional explanation is one suggested by Abdel-Razaq 
et al. [27] where similar data were obtained during an 
investigation of the effects of tianeptine, a tricyclic 
antidepressant, on mitochondrial function. In this study 
it was suggested that the up-regulation of electron 
supply to the respiratory chain in the form of reduced 
flavin adenine dinucleotide (FADH2) causes partial 
or complete bypass of mitochondrial complex I, thus 
facilitating maintenance of mitochondrial membrane 
potential regardless of a small decrease in mitochondrial 
complex I activity.
Figure 7: Mitochondrial complex I activity assays. The activity of mitochondrial complex I in the presence of a range of 
concentrations (0.01 μM – 100 μM) of combretastatin A4 (A), thalidomide (B), OGT 2115 (C) or tranilast (D) is depicted relative to activity 
measurements recorded for control samples exposed to 1% DMSO. Data are expressed as means ± SEM for four biologically independent 
repeat experiments (n = 4). The difference between control and treatment groups at each drug concentration was determined by two-way 
ANOVA followed by Dunnett’s multiple comparison test. The asterisk symbol (*) is used to denote statistical significance in the difference 
between values recorded for experimental and control samples (P ≤ 0.05).
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Combretastatin A4 did not induce any significant 
reduction in mitochondrial complex II–III activity 
at any of the concentrations used. This observation 
was also reflected in the absence of alterations to 
mitochondrial membrane potential measured in isolated 
intact mitochondria. Significant concentration-dependent 
bi-phasic alterations to mitochondrial complex IV activity 
were observed when isolated mitochondria were treated 
with increasing concentrations of combretastatin A4. 
The increase in mitochondrial complex IV activity that 
occurred between concentrations of 0.01 μM and 0.4 μM 
may have been due to changes in mitochondrial membrane 
fluidity; alterations in the fluidity of biological membranes 
are known to alter the maximum rate of an enzyme-
catalysed reactions (Vmax) and the substrate concentration 
at which these proceed at half-maximal velocity (Km) [28]. 
Furthermore, multi-phasic, drug concentration-dependent 
changes in mitochondrial complex activity similar to 
those measured here have previously been reported in 
relation to the effects of cannabinoid receptor agonists 
anandamide and Δ-9-tetrahydrocannabinol on the activity 
of mitochondrial complex I and complex II–III [10]. The 
decreased complex IV activity induced by combretastatin 
A4 at concentrations of 12.5 μM and above was likely due 
to a direct inhibitory effect following stabilisation of the 
increased fluidity of the membrane that occurred at lower 
concentrations [10].
Mitochondrial oxygen consumption was reduced by 
approximately 25–55% in the presence of combretastatin 
A4 at concentrations of 10 μM to 30 μM. Given that 
approximately 95% of cellular oxygen consumption occurs 
as a consequence of the redox reaction between electrons, 
protons and molecular oxygen at mitochondrial complex IV, 
this observation would usually provide a strong indication 
for effective blockade of mitochondrial electron transport 
[29]. The fact that mitochondrial membrane potential was 
unchanged is not too surprising, as it is possible to have 
decreases in mitochondrial oxygen consumption in the 
absence of changes in mitochondrial membrane potential. 
Mitochondrial oxygen consumption is a much more 
sensitive indicator of oxidative phosphorylation and the 
levels of inhibitors required to effect a change are much 
lower than those required to cause an immediate change in 
mitochondrial membrane potential [30].
Figure 8: Mitochondrial complex II–III activity assays. The activity of mitochondrial complex II–III in the presence of a range 
of concentrations (0 μM–100 μM) of combretastatin A4 (A) thalidomide (B) OGT 2115 (C) or tranilast (D) is depicted relative to activity 
measurements recorded for control samples exposed to 1% DMSO. Data are expressed as means ± SEM for four independent experiments 
(n = 4). The difference between control and treatment groups at each drug concentration was determined by two-way ANOVA followed 
by Dunnett’s multiple comparison test. The asterisk symbol (*) is used to denote statistical significance in the difference between values 
recorded for experimental and control samples (P ≤ 0.05).
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An alternative explanation is that reactive 
derivatives of combretastatin A4 were generated within the 
electrode incubation chamber and the oxidation of these 
compounds was able to lead to the direct consumption 
of oxygen via a chemical reaction. In support of this, it 
has been reported that two ortho-quinone derivatives of 
combretastatin A1 (a structural analogue of combretastatin 
A4) are generated in the presence of glutathione by the 
oxidative action of peroxidase enzymes. These compounds 
were shown to cause significant reductions in oxygen 
tension during polarographic measurements and this 
effect was significantly increased in the presence of 
glutathione [31]. Mitochondria are known to contain a 
number of peroxidase enzymes (including glutathione 
peroxidase and cytochrome c peroxidase) and glutathione 
levels at concentrations comparable to those of the cytosol 
(approximately 5 mM) [32–34]. Therefore, it is possible 
that reactive combretastatin A4 derivatives could have 
been generated in solution during the polarographic 
measurement of mitochondrial oxygen consumption, 
and that this subsequently led to the observed reduction 
in oxygen levels in the absence of altered mitochondrial 
membrane potential.
Thalidomide
Previous studies have demonstrated a 
mitochondrial effect of thalidomide and its analogues 
on the Jurkat T cell line, used for the study of 
acute T cell lymphoma [35]. Our data supports 
this, as thalidomide was able to reduce MCF-7 
cell viability and induced a significant increase in 
caspase-3 activity at around 8 hours post-exposure. 
However, unlike combretastatin A4, morphological 
changes indicative of apoptosis were not evident after 
24 hours exposure to 100 μM thalidomide. Furthermore, 
thalidomide was only able to decrease NCI-H460 cell 
viability at a concentration of 100 μM. It has previously 
been reported that thalidomide was able to cause an 
approximate 50% reduction in NCI-H460 cell viability 
at a concentration of 3.87 μM [36]; a much lower 
concentration than that seen to reduce cell viability in this 
Figure 9: Mitochondrial complex IV activity assays. The activity of mitochondrial complex IV in the presence of a range of 
concentrations (0 μM–100 μM) of combretastatin A4 (A) thalidomide (B) OGT 2115 (C) or tranilast (D) is depicted relative to activity 
measurements recorded for control samples exposed to 1% DMSO. Data are expressed as means ± SEM for four independent experiments 
(n = 4). The difference between control and treatment groups at each drug concentration was determined by two-way ANOVA followed 
by Dunnett’s multiple comparison test. The asterisk symbol (*) is used to denote statistical significance in the difference between values 
recorded for experimental and control samples (P ≤ 0.05).
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present study. However, the cytotoxicity assays previously 
reported were undertaken over a much longer duration 
[36]. These contrasting findings suggest that the cytotoxic 
effects of thalidomide in vitro are both concentration-
dependent and time-dependent. Thalidomide is regarded 
as a pro-apoptotic agent, and this cell death modality has 
been reported previously in a NCI-H460 cancer cell model 
[37]. The data from the caspase-3 activity assays indicate 
that apoptosis was the mechanism of cell death in the 
presence of thalidomide, which led to reductions in MTT 
staining measured in the NCI-H460 cells. Furthermore, 
in the NCI-H460 cells cultured in the presence of 
thalidomide, our data showed morphological changes 
characteristic of apoptosis.
Thalidomide elicited a concentration-dependent 
decrease in mitochondrial complex I activity at 
concentrations of 0.1 μM to 6.25 μM and maintained 
decreased activity at around 55% of control values 
between 6.25 μM and 100 μM. While significant decreases 
in mitochondrial complex I activity were measured at 
thalidomide concentrations of 10 μM to 30 μM, these 
concentrations did not produce a significant decrease in 
mitochondrial oxygen consumption or transmembrane 
potential. The mitochondrial threshold hypothesis and 
the effective bypass of mitochondrial complex I, as 
proposed for combretastatin A4, could also explain these 
observations. Bi-phasic modulation of complex IV activity 
by thalidomide was observed, similar to that which was 
observed in the case of combretastatin A4. However, in 
the case of thalidomide no reduction in mitochondrial 
complex II–III activity was present.
Tranilast
Tranilast concentrations of 10 μM to 30 μM resulted 
in small concentration-dependent reductions in complex 
II-linked mitochondrial membrane potential in isolated 
rat heart mitochondria. These reductions in mitochondrial 
membrane potential may have been the result of inhibition 
of respiratory chain components or non-respiratory chain 
mitochondrial enzymes, such as those of the tricarboxylic 
acid cycle (TCA cycle). In addition, the rotenone-induced 
inhibition of complex I necessary for measurement of 
transmembrane potential under FADH2-linked respiration 
may have potentiated this effect; the inhibition of 
complex I activity is known to lead to an increased 
intra-mitochondrial NADH/NAD+ ratio [38, 39] and the 
subsequent feedback inhibition of the TCA cycle would 
lead to a reduction in mitochondrial FADH2 levels, thus 
making the effects of any further inhibition of the TCA 
cycle more potent.
Tranilast was able to induce significant inhibition 
of mitochondrial complex I activity at all concentrations 
used. This decrease in activity was maintained at around 
40–45% of control values at concentrations between 
0.098 μM and 3.125 μM, after which a concentration-
dependent reduction in complex I activity was evident. At 
100 μM tranilast, the activity of complex I was reduced 
to approximately 30% of control values. In addition, 
tranilast concentrations of 10 μM to 30 μM resulted in a 
34–44% decrease in mitochondrial oxygen consumption, 
and concentration-dependent reductions in mitochondrial 
transmembrane potential in the presence of complex 
I-linked respiration. All of these data suggests that tranilast 
is a specific mitochondrial complex I inhibitor as there 
were no significant reductions in mitochondrial complex 
II–III or mitochondrial complex IV activity measured in 
the presence of tranilast. 
In the MCF-7 cell model, there was no evidence 
of a significant decrease in cell viability at tranilast 
concentrations of 1 nM to 10 μM. However, viable cell 
mass was significantly reduced, to around 75% of control 
values, at a tranilast concentration of 100 μM. These data 
are consistent with the study of Darakhshan and Ghanbari 
[12], who showed that 100 μM tranilast was able to effect 
a comparable 20–40% reduction in MCF-7 cell viability 
after 48 hours exposure. They also demonstrated clear 
evidence of apoptosis as the predominant cell death 
mechanisms that led to the observed reduced cell viability. 
In contrast, the data presented here did not indicate any 
obvious morphological changes under fluorescence 
microscopy, nor was there any evidence of tranilast-
induced changes in caspase-3 activity over time. 
While caspase-dependent apoptotic cell death in 
the presence of tranilast has been demonstrated in other 
human breast cancer cell lines [40], it still remains unclear 
as to how tranilast-induced apoptosis is mediated in the 
MCF-7 cell line. However, cathepsin-dependent (caspase-
independent) apoptosis has been demonstrated previously 
[41]. Hence, the low caspase-3 activity in conjunction 
with significantly reduced viable cell mass may indicate 
caspase-independent apoptosis being induced by tranilast 
in the MCF-7 cell model [41]. An alternative explanation is 
that the small inhibition of complex I and resultant changes 
in integrated mitochondrial functions demonstrated at 
high tranilast concentrations are enough to significantly 
decrease ATP production such that cell proliferation is 
slowed and the number of viable cells present in treated 
samples is reduced compared to controls in the absence of 
cytotoxic effects.
In contrast to the findings in the MCF-7 cell line, 
tranilast did not elicit any reduction in cell viability in the 
NCI-H460 cell line. Cell morphology appeared unaltered 
after 24 hours in the presence of 100 μM tranilast, and 
caspase-3 activity was not increased over the same period 
of time at this concentration. At present there is a lack 
of other scientific literature data with which to compare 
these observations. However, NCI-H460 cells are known 
to show metabolic adaptations for significantly increased 
glycolytic energy metabolism, and such a glycolytic 
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phenotype is associated with resistance to apoptosis [42]. 
Therefore, it seems likely that NCI-H460 cells were able 
to circumvent any reduction in mitochondrial oxidative 
phosphorylation induced by tranilast by increasing 
glycolytic ATP synthesis to meet cellular energy 
requirements, thus facilitating cell survival.
OGT 2115
When exposed to 10 μM OGT 2115, the oxygen 
consumption rate of isolated rat heart mitochondria was 
significantly inhibited. Further addition of OGT 2115 
caused very little change to the already largely decreased 
oxygen consumption rate. A single 10 μM dose of OGT 
2115 also caused a rapid mitochondrial hyperpolarisation 
that was followed by a large, rapid depolarisation 
and an almost complete collapse of mitochondrial 
membrane potential. As with oxygen consumption 
measurements, the pattern of change in mitochondrial 
membrane potential occurred independent of increased 
OGT 2115 concentration. The initial hyperpolarisation 
of the mitochondrial membrane observed following 
addition of OGT 2115 to isolated mitochondria suggests 
inhibition of the function of the mitochondrial ATP 
synthase complex (mitochondrial complex V), similar 
to that known to be elicited by the classical complex V 
inhibitor oligomycin [43]; protons are blocked from 
entering the mitochondrial matrix and thus are sequestered 
outside of the inner mitochondrial membrane causing a 
resultant hyperpolarisation and also diminished utilisation 
of oxygen at mitochondrial complex IV. Inhibition 
of complex V leads to a hyperpolarisation of the 
mitochondrial membrane potential [44], followed by its 
collapse due to the electrostatic breakdown of the potential 
(effectively electrical “arcing”) as the charge density 
across the mitochondria inner membrane becomes too 
large. This is followed often by the physical breakdown of 
the mitochondrial inner membrane, and its lysis, leading to 
a complete collapse of the inner mitochondrial membrane 
potential [30, 45].
OGT 2115 was shown to induce a concentration-
dependent reduction in the activity of mitochondrial 
complex I, complex II–III and complex IV. Inhibition of 
the mitochondrial respiratory chain at complex I and/
or complex III in particular is known to increase the 
mitochondrial production of reactive oxygen species 
(ROS) [46, 47]. The rapid release of ROS that would likely 
result from the actions of OGT 2115 is likely to overwhelm 
mitochondrial and cellular reactive oxygen species 
detoxification modalities such as superoxide dismutase, 
glutathione peroxidase, catalase, glutathione, vitamin 
C, vitamin E and other free radical scavenging systems, 
resulting ultimately in significant mitochondrial and cellular 
damage and a direct adverse effect on cellular integrity.
The data obtained from both MCF-7 and NCI-H460 
cell models supports the suggested mitochondrial 
mechanisms of OGT 2115 action. The significant 
reduction in cell viability at OGT 2115 concentrations 
greater than 0.1 μM is suggestive of an agent that has a 
significant effect on cellular physiology. The changes to 
the morphology of the remaining adherent MCF-7 and 
NCI-H460 observed under fluorescence microscopy 
were characteristic of necrosis and the complete absence 
of changes in caspase-3 activity over the time frame of 
the experiments strengthens the argument for necrosis 
being the predominant cell death modality leading to 
the recorded reduction in viable cancer cell mass in the 
presence of OGT 2115.
OGT 2115 has been shown to be an inhibitor of 
the enzyme heparanase [14, 48]. However, OGT 2115 
has been little studied, and It is clear from the emerging 
scientific literature that the specific molecular targets 
and actions of many drugs including the four drugs we 
specifically chose are not completely understood and 
that although, for instance, OGT 2115 is a heparanase 
inhibitor, that may in fact not be its major mechanism 
of action in cancer cells either in vitro or in vivo. Many 
drugs have been shown to have multiple targets [49], and 
our focus has been on drugs that could potentially affect 
mitochondrial function and cause selective cancer cell 
death, whilst sparing normal cells.
The data presented here strongly supports the 
hypothesis that the anti-angiogenic drugs combretastatin 
A4, thalidomide, OGT 2115 and tranilast all have 
mitochondrial targets in addition to their documented 
actions as anti-angiogenic agents. Our data show 
decreases in oxygen consumption in the presence of 
combretastatin A4 and tranilast without significant 
changes in mitochondrial membrane potential. This is in 
keeping with what is already known concerning control 
of oxidative phosphorylation, as large changes in oxygen 
consumption may be associated with relatively small 
changes in mitochondrial membrane potential due to the 
relationship between the fluxes through the three essential 
components responsible for the control of oxidative 
phosphorylation, those of substrate oxidation, ATP 
turnover and proton leak [30]. Mitochondrial membrane 
potential and mitochondrial oxygen consumption are 
not inextricably linked, as the factors that control one do 
not always control the other. It is possible to maintain a 
steady mitochondrial membrane potential in the presence 
of decreased electron transport, as other factors besides 
passage of electrons down the respiratory chain control 
mitochondrial membrane potential. These include electron 
slip and leak associated with uncoupling proteins, as well 
as substrate and ion transport by the malate aspartate 
shuttle, the adenine nucleotide transporter and the calcium 
uniporter [50], all of which can affect the mitochondrial 
membrane potential [26, 30]. In the case of the anti-
angiogenic compounds combretastatin A4 and tranilast, 
it is possible that these compounds are inhibitors of 
mitochondrial uncoupling proteins, able to inhibit proton 
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leak, stabilising mitochondrial membrane potential, whilst 
also decreasing mitochondrial complex I activity.
Our data indicate that combretastatin A4, 
thalidomide, OGT 2115 and tranilast, all anti-angiogenic 
drugs with diverse molecular structures and reported 
biological actions, are able to directly affect cancer 
cell viability and also have effects on mitochondrial 
function. While the ability to modulate mitochondrial 
physiology does not always appear to translate to 
direct anti-cancer action in a two-dimensional MCF-7 
and NCI-H460 cell models in vitro, OGT 2115 and 
tranilast show clear evidence of having direct effects 
on mitochondrial activity that are able to cause a direct 
reduction in cancer cell viability. Tranilast is a mitochondrial 
complex I inhibitor and OGT 2115 has significant effects 
on the integrated function of isolated mitochondria that 
translate into potent cytotoxic action; potentially by 
causing mitochondrial dysfunction through increased ROS 
production and/or causing formation of the mitochondrial 
permeability transition pore [26, 50]. The differences in the 
observed effects of these compounds highlight the diverse 
array of potential mechanisms by which mitochondrial 
physiology may be modulated to achieve anti-cancer action. 
Furthermore, the observation that anti-angiogenic drugs, 
originally thought to act via several extra-mitochondrial 
pathways, do in fact possess significant ability to modulate 
mitochondrial function clearly adds significant credibility to 
the hypothesis that a considerable proportion of the action of 
some anti-angiogenic drugs might be at mitochondrial sites. 
When taken together, these observations strengthen the case 
for the future investigation and development of anti-cancer 
therapies that specifically target cancer cell mitochondria for 
both inhibition of angiogenesis and stimulation of cell death.
There appears to be no scientific literature available 
(apart from our control data), on the concentration 
dependent properties of DMSO on intact isolated 
mitochondrial. However, previous studies on cultured 
astrocytes have shown that exposure of cultured astrocytes 
to 1% DMSO for 24 hours decreased cell viability and 
caused mitochondrial swelling, decreased mitochondrial 
membrane potential increased reactive oxygen species 
production, and subsequent cytochrome c release and 
caspase-3 activation [51]. These data support our previous 
assertions that drugs and their solvents can indeed 
modulate mitochondrial membrane fluidity [9, 10]. 
Further work on DMSO itself has demonstrated that in 
phospholipid membrane models, DMSO is observed to 
exhibit three distinct modes of action, each over a different 
concentration range. At increasing concentrations, DMSO 
induces membrane thinning and increases fluidity of the 
membrane’s hydrophobic core, the induction of transient 
water pores, the desorption of individual lipid molecules 
the membrane, and finally by disintegration of the bilayer 
structure [52].
Little is known of tissue drug concentrations 
in man during cancer chemotherapy, as this would 
entail potentially ethically unacceptable serial biopsies 
of tissue. However, tissue drug concentrations are 
likely to vary very much depending on differences 
in tissue and cellular (cancer versus normal cell) 
metabolism, for example liver and other tissues having 
a variety of drug metabolism enzyme systems including 
cytochrome P450’s. We have specifically chosen to 
use a concentration of 100 μM in some of the studies 
detailed here and this is because we feel that tissue (as 
opposed to plasma) concentrations of drugs in man are 
likely to be much higher than previously thought. This 
has been demonstrated by Weigman et al. [53], who 
showed that the concentration of clomipramine and its 
active metabolite desmethylclomipramine reaches almost 
100 μM in vivo, in rat brain tissue, 4 hours after the last 
oral dose of clomipramine.
In conclusion, we feel that the data presented in 
this manuscript strongly supports the increasing evidence 
that many drugs have complex molecular mechanisms of 
action and more than one specific receptor/target, some 
of which are able to modulate cell metabolism at the 
mitochondrial level and bring about cancer cell death. 
MATERIALS AND METHODS
Eagle’s Minimum Essential Medium (EMEM) 
basal cell culture medium, RPMI-1640 basal cell culture 
medium and foetal bovine serum (FBS) were purchased 
from Life Technologies Ltd. (Paisley, U.K.). All chemical 
reagents used as described in subsequent sections 
were of the highest quality available and were sourced 
from Sigma-Aldrich Company Ltd. (Dorset, U.K.). 
Combretastatin A4, thalidomide and tranilast were sourced 
from Abcam plc. (Cambridge, U.K.). OGT 2115 was 
sourced from Tocris Bioscience (Bristol, U.K.). All anti-
angiogenic drug compounds were dissolved in dimethyl 
sulphoxide (DMSO) to produce stock solutions of 10mM. 
Stock solutions were diluted in either cell culture medium 
or the appropriate assay buffer in order to achieve the 
desired final concentrations used during each experimental 
procedure.
Cell culture
MCF-7 and NCI-H460 cells were obtained as fully 
authenticated cryogenically frozen cultures from the 
American Type Culture Collection (ATCC) (Manassas, 
VA, U.S.A.). MCF-7 cells were maintained in vitro as 
adherent monolayer cultures in a complete cell culture 
medium comprised of EMEM supplemented with 10% 
(v/v) FBS while NCI-H460 cells were maintained as 
adherent monolayer cultures in a complete medium 
comprised of RPMI-1640 supplemented with 10% (v/v) 
FBS. Cell culture medium was maintained at physiological 
pH and temperature by equilibration with a mixture of 
5% CO2 and 95% air at 37
oC inside a humidified water-
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jacketed incubator. Nutrient-depleted culture medium was 
exchanged for an equal volume of fresh complete medium 
at 48-hour intervals. Cells were sub-cultured or harvested 
for use at 70–80 % confluency by incubation at 37oC with 
0.25% trypsin-EDTA solution for 5 minutes.
MTT assay
The cytotoxic effect of each anti-angiogenic 
drug was determined using an MTT assay. Cells were 
seeded into 96-well cluster plates at a density of 2.0 
× 103 cells per well in a 200 µl volume of complete 
medium and placed into incubation at 37oC overnight. 
Spent culture medium was removed following overnight 
incubation and replaced with an equal volume of 
complete medium containing a range of concentrations 
(1 nM–100 µM) of anti-angiogenic drug. Growth 
controls (cells with culture medium), vehicle controls 
(cells with culture medium + 1% DMSO) and blank 
wells (culture medium only) were included on each 
plate. Plates were then replaced in the incubator for 
72 hours. After a 72-hour incubation period, the MTT 
assay procedure was undertaken according to the 
method described previously [8], except that incubation 
time in the presence of MTT solution was adjusted to 
3 hours.
Fluorescence microscopy
Cells were grown to 70–80% confluency on round 
glass cover slips (1.5 mm thickness, 12 mm diameter) 
pre-coated with 150–300 kDa poly-L-lysine in flat-
bottomed 24-well cluster plates. The nutrient-depleted 
medium was removed from each well and replaced with 
an equal volume of complete medium containing 100 
µM of anti-angiogenic drug or 1% DMSO in complete 
medium (negative control). A further 24-hour incubation 
period was then undertaken, after which the drug-
containing medium was removed from all wells and the 
adherent cell layer washed three times with phosphate 
buffered saline (PBS) prior to fixation and staining. 
Cells were fixed for 15 minutes using 3.7% methanol-
free formaldehyde in PBS and then subsequently washed 
three times in PBS. Cells were permeabilised using 
0.1% Triton X-100 in PBS for 5 minutes, followed by 
three more washes in PBS. Cytoskeletal filamentous 
actin (F-actin) and double-stranded DNA (dsDNA) 
were stained using Alexa Fluor® 488-phalloidin and 
4′,6-diamidino-2-phenylindole (DAPI) (both sourced 
from Life Technologies Ltd.) according to the supplier’s 
instructions. Samples were air dried and mounted onto 
glass microscope slides in a minimal volume of ProLong® 
Gold anti-fade mounting medium (Life Technologies 
Ltd.) according to the supplier’s instructions. All samples 
were imaged at X1000 magnification using a Nikon 
Eclipse E-800 upright microscope fitted with a Nikon 
DS-Fi1 high-definition colour camera head and a Nikon 
DS-L2 camera control unit (Nikon U.K. Ltd., Kingston 
upon Thames, U.K.).
Measurement of Caspase-3 activity
Caspase-3 activity was measured directly by its 
ability to enzymatically cleave the fluorogenic substrate 
acetyl-Asp-Glu-Val-Asp-aminomethylcoumarin (Ac-
DEVD-AMC), as described previously [8, 27]. Cells 
were seeded into 60 mm polystyrene tissue culture dishes, 
supplemented with 5ml of complete culture medium and 
grown to 70–80% confluency. Once the desired level of 
coverage was reached, the medium within the dishes was 
exchanged for an equal volume of complete medium 
containing either 100 µM of each anti-angiogenic drug, 
1% DMSO (negative control) or 1 µM staurosporine, used 
as a positive control for induction of apoptosis [17]. Dishes 
were then placed into incubation for time intervals of 0, 1, 
2, 4, 8, 16 and 24 hours. At each time-point, dishes were 
removed from incubation, placed directly on ice and cells 
harvested using a plastic cell scraper. Both medium and 
scraped cells were transferred to pre-cooled centrifuge 
tubes and centrifugation undertaken for 10 minutes at 
200 × g and 4oC. The resultant supernatant was discarded 
and each pellet carefully washed twice with ice cold PBS. 
Cell lysis was achieved by incubation for 30 minutes in 
ice-cold lysis buffer (100 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 100mM sodium 
chloride, 1 mM EDTA, 0.1% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulphonate (CHAPS) and 
10% sucrose dissolved in ultrapure (18.2MΩ-cm) distilled 
water and adjusted to pH 7.4 at 4°C) with continuous 
agitation. In order to ensure all samples remained 
chemically reduced, dithiothreitol (DTT) was added to a 
final concentration of 10 mM on the day of use. Following 
lysis, samples were subjected to centrifugation at 10,000 
× g for 10 minutes at 4oC in order to produce a cytosolic 
fraction (supernatant), which was then carefully removed 
and stored at −80oC until required for measurement 
caspase-3 activity. Cytosolic extracts were added to 
96-well black polystyrene clear-bottomed fluorescence 
assay plates. The pan-caspase inhibitor Z-Val-Ala-Asp-
fluoromethylketone (Z-VAD-FMK) was added to half of 
the samples (f.c. 10 µM) and incubation undertaken for 
30 minutes on a heated plate shaker maintained at 37oC. 
Subsequently, Ac-DEVD-AMC was added to all wells (f.c. 
20 µM) and further incubation undertaken in complete 
darkness for 1 hour. Final reaction volume in all wells was 
300 µl. The caspase-dependent production of fluorescent 
7-amino-4-methylcoumarin (AMC) from the parent AC-
DEVD-AMC molecule was measured by the fluorescence 
intensity at an excitation wavelength of 350 nm and an 
emission wavelength of 450 nm using a Tecan Infinite 200 
Pro Series multimode microplate reader (Tecan UK Ltd., 
Reading U.K.).
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Isolation of rat heart mitochondria
Rat heart mitochondria were prepared from the 
hearts of 250 g adult Lister rats using homogenisation and 
differential velocity centrifugation as previously described 
[50].
Measurement of mitochondrial oxygen 
consumption
Mitochondrial oxygen consumption was measured 
polarographically using a Clarke-type oxygen electrode 
(Rank Brothers Ltd., Cambridge, U.K.) in respiration state 
3 (+ ADP) at 37°C with 10 mM malate + 10 mM glutamate 
as substrates, as described previously [54]. 0.25 mg of 
mitochondrial protein was used in all assays. In separate 
assays, combretastatin A4, thalidomide, OGT 2115 and 
tranilast were added to the mitochondrial suspension in the 
oxygen electrode chamber to achieve final concentrations 
of 10 µM, 20 µM or 30 µM and incubated for 5 minutes 
before the addition of ADP.
Measurement of mitochondrial membrane 
potential
Mitochondrial membrane potential measurements 
were made fluorimetrically using 0.2 µM rhodamine-123 at 
37°C. Complex I (NADH)-linked changes in mitochondrial 
membrane potential were measured using 10 mM malate 
and 10 mM glutamate as substrates while complex II 
(FADH2)-linked changes in mitochondrial membrane 
potential were made in the presence of 1 µM rotenone using 
10 mM succinate as substrate. Both assay procedures were 
undertaken according to the methods outlined previously 
[27]. 0.25 mg of mitochondrial protein was used in all 
assays. The mitochondrial uncoupling protonophore FCCP 
was used (f.c. 10 µM) in order to completely dissipate any 
transmembrane potential remaining following the addition 
of anti-angiogenic agents.
Measurement of mitochondrial complex I, 
complex II–III, complex IV activities
Freeze-thawed rat heart mitochondria were re-
suspended in a respiration buffer solution (100 mM KCl, 
75 mM mannitol, 25mM sucrose, 10 mM Tris, 0.1 mM 
EDTA, and 10mM phosphate-Tris in ultrapure distilled 
water, adjusted to pH 7.4 at 37oC) and aliquoted as 240 µl 
volumes into 96-well cluster plates at 37°C for 15 minutes 
to thermostabilise. Drugs (or vehicle) were then added 
in a volume of 10 µl to give a range of concentrations 
from 0.01 µM to 100 µM and plates were incubated for 
a further 5 minutes at 37°C to allow for drug binding. 
Samples were then pipetted off from the drug-mitochondria 
suspensions and added to separate assay plates containing 
the components needed for the assay of mitochondrial 
complex I, complex II–III or complex IV activity. 0.25 mg 
of mitochondrial protein was used in all assays. The 
specific activity of mitochondrial complex I (NADH-
ubiquinone oxidoreductase) [EC 1.6.5.3] was measured 
spectrophotometrically as the rotenone sensitive rate of 
NADH oxidation at 340 nm and 37oC. The activity of 
mitochondrial complex II–III [EC 1.5.3.1] was measured 
spectrophotometrically as the antimycin A sensitive rate of 
cytochrome c reduction at 550 nm and 37oC. The activity 
of mitochondrial complex IV (cytochrome c oxidase) [EC 
1.9.3.1] was measured spectrophotometrically as the rate of 
cytochrome c oxidation at 550 nm and 37oC. In all cases, 
the methods undertaken were as previously described [8].
Protein assay
Cytosolic and mitochondrial protein concentrations 
were determined, using a modified microplate version of 
the Lowry protein assay described previously [8]. Bovine 
serum albumin (0–200 µg/ml) was used as a concentration 
standard.
Statistical analyses
All data displayed are the result of at least n = 3 
independent experiments. Data are expressed as means ± 
the standard error of the mean. Statistical analyses were 
performed using GraphPad Prism 6 (GraphPad Software, 
Inc., La Jolla, U.S.A.). The statistical test undertaken for 
each experimental data set is indicated in the respective 
figure legend. Statistical significance was attributed when 
a P-value of ≤ 0.05 was obtained.
Dedication
Mr. Lewis Quayle and Dr. Timothy E. Bates would like 
to dedicate all the work detailed in this manuscript to their 
fathers, Barry Quayle (1966–2006) and Bryan Arthur Bates 
(1927–1975) both of whom died (far too early) from cancer. 
We miss them greatly and are working towards a cure.
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